LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout

If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%. That is the pitch for LABU in one sentence, and also the warning, because the same fund is down 87% over five years while XBI itself is essentially flat across that stretch.

Both things are true. Both things are the product working exactly as designed. The trick with LABU is understanding which of those two outcomes you are actually buying.

What the Fund Is Built To Do

LABU targets 3x the daily return of the S&P Biotechnology Select Industry Index, the same benchmark XBI tracks. The leverage resets every afternoon. Hold it for one good day in biotech and you get something close to triple the index move. Hold it through a year of chop and the daily compounding starts working against you, sometimes brutally, even if the index finishes higher than where it started.

Biotech is a uniquely good sector to lever and a uniquely dangerous one. XBI is equal-weighted across roughly 130 names, so a single FDA approval at a $4 billion mid-cap can move the index as much as one at a $40 billion incumbent. The sector goes nowhere for long stretches and then sprints. A 3x version of that pattern can deliver triple-digit returns over twelve months while quietly turning into a disaster over five.

The Setup This Spring

The breakout case has visible support. XBI is up almost 8% over the past month, 9% year to date, and 65% over twelve months from a depressed starting price near $80 last April. After three years where biotech largely sat out the broader bull market, the sector is finally moving with conviction.

The volatility regime is also more friendly than it has been. The VIX is near 19, down from a March peak above 31. Calm tape preserves the math on daily-reset products. Choppy tape eats it.

Last week supplied a small reminder of the geometry. XBI fell 4%. LABU fell 12%. That is what investors who treat LABU as a slightly spicier biotech ETF keep underestimating.

Does It Deliver

Over a clean trending year, yes. The roughly 235% twelve-month gain on a 65% XBI move is close to the theoretical 3x outcome, with a small drag from fees and rebalancing. Over longer windows the math falls apart.

XBI is essentially flat over five years. LABU is down 87% over the same five years. Over ten years, XBI is up 141%, and LABU is still down 72%. Three times a positive number turned into a deeply negative one because biotech spent most of that decade swinging rather than trending.

That is the whole story of leveraged daily-reset products. They deliver 3x of one-day returns, then reset, then do it again. Long-term compounding works on a different math. The gap between those two things compounds, and against you.

The Tradeoffs Are Not Subtle

1. Volatility decay. Even a year where XBI rallies meaningfully can produce a flat or negative LABU return if the path is choppy. The fund needs trend, not just direction.
2. Binary sector risk. Biotech moves on trial readouts, FDA decisions, and political headlines about drug pricing. A bad week of catalysts can erase months of leveraged gains.
3. Tax friction. Anyone using LABU correctly is rotating in and out, which means short-term capital gains and a tax bill that can quietly take another chunk out of an already volatile return stream.

LABU works as a 1-3% tactical sleeve for traders who think biotech is starting a sustained directional move and who will actually exit when the move ends, but anyone using it as a long-term biotech proxy is fighting the math of the product itself.